Skip to content
You can now search across every topic, entity and event.What's new
Pandemics and Biosecurity
7MAY

B3.13 replicates better in human nasal tissue

4 min read
15:24UTC

NIH/NIAID researchers Flagg and Winski published peer-reviewed evidence on 12 May that the H5N1 strain dominating US dairy cattle replicates more efficiently in human nasal epithelium than any historical H5N1 strain and partly disables the immune alarm that would normally limit early replication.

ScienceDeveloping
Key takeaway

B3.13 outperforms historical H5N1 in human nasal tissue and delays the immune alarm, while surveillance weakens.

NIH/NIAID researchers Flagg and Winski published a study in CDC Emerging Infectious Diseases (DOI: 10.3201/eid3205.260053) on 12 May showing that B3.13 (the clade 2.3.4.4b H5N1 genotype circulating in US dairy cattle since 2024) replicates more efficiently in human nasal epithelium cultures than historical H5N1 strains. 1 The same paper found that B3.13 suppresses ISG (interferon-stimulated gene) responses, the innate immune system's first-line molecular alarm; a virus that triggers fewer ISGs buys more time to replicate before the body mounts a coordinated defence.

The Emory University aerosol study published in PLOS Biology on 1 May had already shown B3.13 present in submicron aerosol particles inside milking-parlour air across 14 California farms . Together, the two papers complete a mechanistic two-step pathway: B3.13 reaches the nasal epithelium via the aerosol route, and once there it replicates efficiently while partially evading innate immunity. Neither paper claims human-to-human transmission is imminent. What they jointly establish is a directional fitness signal that the 2024-era virological profile of B3.13 did not contain.

The EID paper also found that 66% of exposed dairy farm workers carried pre-existing neutralising antibodies against pdm09 H1N1 (the pandemic H1N1 strain from 2009, now endemic globally as a seasonal influenza). 2 The researchers suggest this cross-immunity may explain why the CDC human case counter has stood at 71 since 6 March, even as the national dairy cattle total crossed 1,047 cases in 17 states. That explanation carries a corollary: workers WHO missed 2009 pandemic vaccination or WHO received only attenuated protection carry reduced cover if human spread accelerates.

The ISG suppression mechanism adds a clinical-detection wrinkle. ISG induction produces the fever and cytokine symptoms that typically prompt dairy workers to seek testing; a strain that delays ISG activation could circulate longer before self-reporting, compressing the window between exposure and detection. Bangladesh and Cambodia logged four human H5N1 cases by February, all from poultry contact , confirming the dairy-cattle route to human exposure remains less documented. The defensive side has one concrete advance: CEPI's (Coalition for Epidemic Preparedness Innovations) mRNA H5N1 vaccine candidate entered Phase 3 trial on 22 April , the furthest any such candidate has reached.

Deep Analysis

In plain English

**H5N1** is a bird flu virus that has been spreading through US dairy cattle since 2024. Scientists were worried about whether it could infect humans more easily, and this new study answers part of that question. Researchers at the **National Institute of Allergy and Infectious Diseases** grew human nasal cells in a lab and exposed them to the specific strain called **B3.13** that lives in US dairy herds. They found it copied itself more efficiently in those cells than older bird flu strains did, and it also partially switched off the cells' first alarm signal (the immune response that normally slows a virus down). The reassuring part: about two-thirds of dairy farm workers already have leftover immune protection from the 2009 swine flu pandemic. Scientists think this is probably why human cases have stayed rare even though the virus has been improving at getting into human nose cells. The worry is that this protection will not last forever, especially as the virus keeps spreading across more herds.

Deep Analysis
Root Causes

Three structural conditions combine to produce this finding. First, B3.13 evolved in the **mammary epithelium** of dairy cattle, a tissue environment that shares sialic acid receptor distribution with human nasal epithelium, creating inadvertent selective pressure for human nasal-compatible variants without any direct human infection required.

Second, the ISG suppression pathway B3.13 uses is the same interferon-evasion strategy seen in multiple pandemic-capable strains. The **NIAID/NIH** team's finding that B3.13 suppresses ISG responses below historical H5N1 levels is not a random mutation; it reflects cumulative selection across two years of continuous dairy-herd circulation.

Third, the surveillance architecture that might catch an early human adaptation event was partially dismantled on 1 May 2026 when **USDA APHIS** ended mandatory interstate testing, removing the movement-checkpoint layer that historically detected infections before they crossed state lines.

What could happen next?
  • Risk

    If B3.13 acquires mutations that allow it to partially evade pdm09 antibodies, the 66% workforce-immunity buffer collapses and occupational exposure converts from rare to frequent.

    Medium term · 0.65
  • Consequence

    CDC and USDA face regulatory pressure to revise dairy-worker PPE guidance to include N95 respirators for milking operations, following the Emory aerosol evidence (ID:3109) and now nasal-fitness confirmation.

    Short term · 0.75
  • Precedent

    The EID paper establishes nasal-epithelium culture assays as the standard B3.13 fitness benchmark, meaning future variant comparisons will be assessed against this baseline.

    Long term · 0.8
First Reported In

Update #2 · B3.13 gets better at humans as testing ends

CDC Emerging Infectious Diseases· 12 May 2026
Read original
Causes and effects
This Event
B3.13 replicates better in human nasal tissue
The first mechanistic characterisation of B3.13 in human nasal tissue establishes a fitness trajectory that surveillance infrastructure is no longer fully equipped to track.
Different Perspectives
Germany (evacuation recipient)
Germany (evacuation recipient)
Germany received the Bundibugyo outbreak's third international medical evacuation on 13 July, a US humanitarian worker infected in Bunia on 10 July. The evacuation, following a French doctor's 24 June departure and May's first US case, tests whether isolation and biocontainment protocols scale beyond DR Congo's own borders.
Pennsylvania Department of Public Health
Pennsylvania Department of Public Health
PDPH retested and retracted a false-positive measles wastewater signal on 6 July, then confirmed and publicised a real airport exposure from 4 July, with commissioner Palak Raval-Nelson stressing there is no broad threat to the general public. The national count, 2,231 cases across 42 states by 9 July, is on pace to beat 2025's 2,289-case record before September.
World Health Organization
World Health Organization
WHO published its first dedicated Blueprint on fungal disease and antifungal resistance on 1 July, estimating more than 300 million people suffer serious fungal disease annually. The Blueprint names the gap in WHO's own AMR strategy rather than waiting for an external audit to force the admission.
Africa CDC
Africa CDC
Africa CDC issued a formal 11 July appeal for responder protection, training and psychosocial support after health-worker infections tripled from 34 to 112 in a month. The appeal repeats June's unmet call for a rapid Bundibugyo diagnostic test, showing the ask has shifted from tools to basic safety and pay.
Front-line health workers, Ituri Province
Front-line health workers, Ituri Province
Health workers in Ituri Province walked off the job or threatened to strike over unpaid hazard pay and delayed salaries, even as responder infections tripled to 112 with 35 dead. Their absence narrows the isolation workforce the CDC's model says must reach 70% coverage to avoid a 20,000-case worst case.
ECDC
ECDC
ECDC co-published the isolation and contact-tracing figures behind WHO's DON612, tracking Ituri's isolation rate rising from 35 to 44 percent while still rating EU/EEA import risk as very low. Brussels backs the WHO line against travel restrictions, the position France's own contact-tracing response, not the US entry ban, actually validated.